One of the objectives in the treatment of the inflammatory bowel disease (IBD) is improving the patient's quality of life. However, we do not dispose of validated criteria to determine the questionnaire's scoring threshold that has to be reached in order to be able to assert that the patients' quality of life has normalized. Objective: To determine the normality punctuation cutoff in the IBD specific quality of life questionnaire IBDQ-36. Method: Cross-sectional study in a random sample of IBD patients, who have completed the questionnaires IBDQ-36 and EuroQol-5D. The IBDQ-36 normality was calculated according to its equivalence with the EuroQol-5D tariff ≥ 0.90, which corresponds to the 95% CI of the average obtained in a Spanish general population. Results: 218 patients were included. According to the EuroQol-5D tariff, 70 patients were considered to have a normal quality of life and 148 a quality of life poorer than the general population. The IBDQ-36 scoring was significantly higher in the normal quality of life group (222.9 ± 22.8 vs. 171.4 ± 44.8 in the bad quality of life group, p b 0.001). According to the linear regression between IBDQ-36 and EuroQol-5D, the cutoff point is 209, with a sensitivity and specificity to predict normality of 0.74 and 0.71 respectively. Conclusions: Scores of the IBDQ-36 equal or superior to 209 suggest quality of life comparable to that perceived by the general population. This study allowed to set a threshold of normality in the management of the inflammatory bowel diseases.
Introduction
The inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disorder of the intestine. Both forms of IBD usually follow a relapsing clinical course, with phases of remission alternating with periods of active inflammation. 1 Both UC and CD are known to have higher incidence and prevalence in Northern Europe and North America and lower incidence and prevalence in Central and Southern Europe and South America. 2 In Spain, UC incidence ranges from 0.6 to 8 persons/10 5 /year and 0.4 to 5.5 persons/10 5 /year in CD. 3 IBD has negative repercussions on various dimensions of the patients' quality of life, their families and society. [4] [5] [6] Furthermore, patients with CD and UC are estimated to have a rate of depression three times greater than that of the general population. 7 The quality of life related to health (HRQoL) makes reference to the patient's subjective perception of his/her illness and its impact on everyday life. Therefore, it is as important to take into account the objective state of health as the individual's general satisfaction with his/ her own health. 8 Due to the importance of the HRQoL assessment in IBD patients, several instruments for its measurement have been designed. One of the most commonly used questionnaire is the 32-item version of the IBD Questionnaire (IBDQ-32), published by Guyatt et al. 9 Other questionnaires with proven validity and reliability in patients with IBD are the extended 36-item version of the IBD Questionnaire (IBDQ-36), 10 the Drossman's rating form of IBD patient concerns (RFIPC), 11 the IMPACT Questionnaire, 12 the Cleveland Clinic IBD Scale, 13 or the EuroQol-5D. 14 The IBDQ is recommended to be used routinely as a secondary outcome in all prospective, randomized, controlled trials to ensure that the quality of life is improved in medically treated patients with IBD. 15, 16 One of the advantages of the IBDQ is its sensitivity to promptly reflect the changes in a patient's condition, that is a crucial parameter for the assessment of short-term response to therapeutic interventions. 17 The criteria to measure the effects of a treatment on the patients' quality of life are generally based on the detection of a statistically significant improvement in the punctuation of the questionnaire. Nevertheless, it would be preferable to dispose of a normality cutoff before starting the treatment, as a pre-established objective to be reached. Nowadays, there is little information available related to the definition of the punctuation threshold to be reached to consider that the patient's HRQoL has normalized. In a sample of patients with Crohn's disease, Hlavaty et al. 17 used the Crohn's disease activity index (CDAI) to determine the punctuation threshold of IBDQ-32. On the other hand, Higgins et al. 18 used a yes/no answer dichotomic analysis in a sample of patients with UC. Both of these studies identify normality in quality of life with a remission of the illness activity. But these two concepts, quality of life and disease activity, are different and not always equivalent. Therefore, we consider that the normality threshold in a quality of life questionnaire for patients with EII has to be established with a normal quality of life criteria determined upon the general population. Thus, the aim of present study was to determine the normality punctuation cutoff in the IBD specific quality of life questionnaire IBDQ-36.
Materials and methods

Patients
An observational, cross-sectional study was carried out among a random group of patients with either UC or CD attended in the Unitat Atenció Crohn-Colitis of our Hospital. The diagnosis was based on conventional clinical, endoscopic, radiologic and histological criteria. 1 Basic demographic and clinical data were collected. All the patients completed two HRQoL questionnaires: the disease-specific IBDQ-36 and the generic EuroQol-5D.
HRQOL assessment
The patients' HRQoL was assessed using specific and generic questionnaires. The disease-specific IBDQ-36 is a selfadministered questionnaire translated and validated for its use in Spain. 19 The version of the IBDQ used in the present study was the 36-item version by Love et al. 10 The 36 items are grouped into five domains of health (bowel symptoms, systemic symptoms, functional impairment, social impairment, and emotional function). Responses are scored on a 7-point Likert scale, in which 7 corresponds to the highest level of functioning. The instrument produces five dimension scores and an overall IBDQ score ranging from 36 to 252, where a higher score reflects better HRQoL.
The EuroQol-5D is a short self-administered generic utility measure that provides both a descriptive profile and an overall index for HRQoL. Utility measures are questionnaires based on preferences assigned by the subjects to different degrees of health instead of scores. EuroQol-5D includes five dimensions (mobility, personal care, daily activities, pain, and anxiety-depression) answered on a 3-point scale ranging from no problems (level 1) to extreme problems (level 3). Combining one level of severity from each of the five dimensions generates a number of discrete health states that can be assigned "preference values" ranging from 0, which represents worst health status, to 1 (best health status). The EuroQol-5D also includes a visual analog scale (VAS) that ranges from 0 (worst imaginable health status) to 100 (best imaginable health status) on which patients were asked to mark the point that best reflected their health status on the day of the interview. EuroQol-5D has also been translated and validated in Spanish. 20 As a reference, normed values for a representative sample of 12,245 individuals of the Spanish general population also exist for the EuroQol-5D and we used these as a control for the patients included in the present study. The 95% IC of the EuroQol-5D tariff values obtained in the Spanish general population is 0.9. 
Calculation of the IBDQ-36 cutoff values
The calculation of the IBDQ-36 normality cutoff was performed by using a linear regression analysis between IBDQ-36 and EuroQol-5D. The normality reference taken is the EuroQol-5D ≥ 0.9 tariff, which corresponds to 95% CI obtained in the Spanish general population. The sensitivity and the specificity on the IBDQ normality threshold were calculated by ROC curve analysis.
Statistical analysis
Statistical analysis was carried out by the computerized program SPSS 11.0. According to the Kolomogorov-Smirnov Test, variables conform to normality. Thus, results are expressed as means ± DS. The correlation between the IBDQ-36 values and EuroQol-5D was evaluated by using the Pearson's Correlation Coefficient. Linear regression was used to calculate the corresponding IBDQ-36 and EuroQol-5D. The ROC curves analysis was used to explore the normal punctuation threshold based on EuroQol-5D.
Results
Patient characteristics
218 patients -104 with UC (48%) and 114 with CD (52%) -were included. The clinical characteristics of patients are summarized in Table 1 . In spite of differences between the rate of patients who had undergone surgery and those with the smoking habit, the rest of characteristics in CD and UC patients were similar. As expected due to the transverse design of the study, the majority of the patients included were in clinical remission.
Quality of life in IBD
According to EuroQol-5D values, there were 70 patients (33 with CD and 37 with UC) with a tariff higher than 0.9, which is the equivalent to a normal quality of life. On the other hand, 148 patients (81 with CD and 67 with UC) have a worse than normal quality of life (Table 2) . When comparing the IBDQ-36 punctuation of patients distributed according to the categorization of the EuroQol-5D tariff, average global score of the IBDQ-36 are significantly higher in those patients with normal HRQoL than in those with worse than normal HRQoL (222.9 ± 22.8 vs. 171.4 ± 44.8 respectively, p b 0.001).
There were no significant differences between UC and CD patients concerning the values of the scoring of IBDQ-36, EuroQol-5D tariff and EuroQol-5D VAS (Table 3) . Consequently, the IBDQ-36 cutoff was established by analyzing UC and CD patients together in a same group. 
Correlation between IBDQ-36 and EuroQol-5D
As shown in Fig. 1 , there was a highly significant correlation between the EuroQol-5D and the total store of IBDQ-36 (correlation coefficient: 0.72; p b 0.001, CI 95% [0.65-0.78]).
Cutoff for normal IBDQ-36
The regression lines between the IBDQ-36 and EuroQol-5D corresponded to [57.7 + 169.2 · EuroQol-5D] (Fig. 1) . Taking tariff ≥ 0.9 as EuroQol-5D normality figure, the corresponding IBDQ-36 value on the regression line equation is 209 points. Based on the receiver operating characteristic curves, the sensitivity and specificity of the normal IBDQ-36 cutoff value of 209 to predict normality were 74% and 71%, respectively. As a global measure of the exactness of the proof, the area obtained underneath the ROC curve in IBDQ-36 is 0.85 (Fig. 2) . This result proves the validity of the 209 cutoff in IBDQ-36 for correctly predicting the patients with a normal quality of life.
Discussion
Multiple types of questionnaires are used to measure HRQoL in chronic diseases. In IBD, the most commonly used questionnaire is the IBDQ and, in our context, specifically the 36-items version. This version has proven to obtain equivalent results of those of the 32-items version. 22 Traditionally, to determine the patients' reaction to the treatment of IBD, clinical and/or endoscopic indexes were used. Nevertheless, the improvement on the patients' quality of life is nowadays also regarded as an index for measuring the reaction to the treatment.
In the vast majority of controlled therapeutic trials, the improvement in the quality of life is defined as a statistically significant increase in the scoring of the questionnaires. This measurement of the patient's improvement might not be clinically significant and it should be reinforced with complementary data, such as a normality threshold definition. The present study gives an answer to the need of defining, both in CD and in UC, what IBDQ-36 punctuation score should be reached with the treatment, so as to achieve a quality of life equivalent to that of the general population of reference.
The definition of the normal IBDQ-36 cutoff in our study was not based on clinic or endoscopic indexes but on a normalized HRQoL index in healthy population. We consider the HRQoL to be neither equivalent nor exchangeable with clinic activity, although both are aspects related to the impact of the IBD. HRQoL takes into account the patients' subjective perception of his/her health, whereas the activity indexes are objective measurements which most of the time include biological and endoscopic parameters which are unrelated to the patients' perceptions.
The quality of life reference pattern among our population corresponds to a EuroQol-5D tariff of 0.9. 21 The definition of a normal cutoff value for the IBDQ-36 may lead to some potential limitations, such as differences among sexes or changes with time. The analysis of epidemiological poblational studies carried out by the Official Health Survey of the local Government 23 have shown that the EuroQol-5D tariff average is not influenced by the patient's sex (with an average of 0.9 both in men and women in the 15 to 44 year-old group). In addition, these surveys have also shown that in the last four years of register no significant changes on the EuroQol-5D punctuation have been detected in the age group from 15 to 44 year-old patients (this age range is the same as that of the patients' conforming to our study). These results suggest that the calculated cutoff is independent of the diagnosis of UC or CD, and also independent of sex and stable with time.
All the patients taking part in this study filled in two quality of life questionnaires: the specific IBDQ-36 and the generic referential EuroQol-5D. Along the lines of what was observed in previous studies 6, 24 no differences between CD and UC patients were found. Therefore, the statistical analysis has been carried out in combination with a linear regression analysis of the punctuation between both questionnaires. The IBDQ-36 normality threshold has been established in 209 points, which by analysis of ROC curves, obtains a high sensitivity and specificity with an area under the curve of 0.85. All this indicates that a score of 209 in IBDQ-36 correctly forecasts the inflammatory bowel disease patients with a normal HRQoL.
The published normality threshold criteria 17, 18 for other versions of IBDQ in UC and CD patients have used different methodologies, making it difficult to compare them. All the works published regard clinical activity as a measure used for comparison but, as stated before, we consider preferably to establish the comparison with a normal life quality index from general population.
In conclusion, disposing of a normality cutoff value brings about the advantages of standardizing the objectives of IBD treatment, inasmuch as to the improvement of HRQoL and IBD refers. Scores equal or superior to 209 in the IBDQ-36 questionnaire correspond to a quality of life equal to that perceived by the general population of reference. Such figures should be set as a new goal in the treatment of the inflammatory bowel disease in controlled clinical trials.
